TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05026411

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: T 0 Diffusion Tensor MR
Description: Magnetic resonance images has been taken from 20 individuals with eating disorders before fixed orthodontic treatment

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: T 1 Diffusion Tensor MR
Description: Magnetic resonance images will be taken from 20 individuals with eating disorders after 12 months of orthodontic treatment.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: T 2 Diffusion Tensor MR
Description: Magnetic resonance images will be taken from 20 individuals with eating disorders 6 months after orthodontic treatment finished
Study: NCT00227006

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral lifestyle/weight-loss intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral lifestyle/weight-loss intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral lifestyle/weight-loss intervention
Study: NCT05744284

Intervention type: DEVICE
Intervention: electrocautery
Description: advantages reported in this study in terms of wound infections, healing time, postoperative pain and cosmetic results in association with economic gain for saving in the purchase of scalpels, represent a formidable motivation for the surgeons to abandon the scalpel in favors of diathermy
Study: NCT00332280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMT2003
Study: NCT03181035

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: (18)F-Fluoroazomycin arabinoside
Description: FAZA PET diagnostic testing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimonidazole
Description: oral pimonidazole hypoxia labeling
Study: NCT01484275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Siltuximab
Description: Type=exact, unit=mg/kg, number=15, form=intravenous infusion, route=intravenous use, every 4 weeks until progression to symptomatic multiple myeloma, unacceptable toxicity, withdrawal of consent, or the end of the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Form=intravenous infusion, route=intravenous use route=intravenous, use every 4 weeks until progression to symptomatic multiple myeloma, unacceptable toxicity, withdrawal of consent, or the end of the study.
Study: NCT01681940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamazym
Description: ERT, i.v. infusions weekly
Study: NCT03842397

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kephalios Device 1
Description: The Kephalios Device 1 is an adjustable annuloplasty ring, to be implanted by open surgery, having a hollow structure that comprises a flat rigid ring surrounding a deformable cage. The unique feature of the Kephalios Device 1 is that its annular shape and dimension can be finely adjusted percutaneously by an external actuator (three-balloon catheter) independently in the three areas corresponding to P1, P2 and P3
Study: NCT02485184

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transjugular intrahepatic portosystemic shunt
Description: Transjugular intrahepatic portosystemic shunt refers to an interventional radiological procedure by placing a stent between portal vein and hepatic vein. No specific device was used in the Interventional field.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Non-selective beta blockers
Description: Non-selective beta blockers are the drugs for reducing the portal pressure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic therapy
Description: Endoscopic therapy includes the endoscopic variceal band ligation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anticoagulation
Description: Anticoagulation therapy includes heparin and warfarin.
Study: NCT03106714

Intervention type: DIAGNOSTIC_TEST
Intervention: RT-PCR
Description: Persistence of detectable Zika virus (by RT-PCR test) in all selected body fluids
Study: NCT00851084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aflibercept
Description: administration: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: administration: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxaliplatin
Description: administration: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: administration: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: administration: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic Acid
Description: administration: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folinic Acid
Description: administration: IV infusion
Study: NCT03650023

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chitosan Oligosaccharide (GO2KA1)
Description: Chitosan Oligosaccharide (GO2KA1) capsule was consumed within 15 min, and then 2-h oral sucrose tolerance test was conducted.
Study: NCT03605719

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pelareorep
Description: Given IV
Study: NCT03951688

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental-Multi-modal exercise program
Description: Each home-based session (48) starts with 7 minutes of moderate warm-up exercises focusing on mobility and flexibility. Secondly, the strengthening exercises consist of knee extensions, knee flexions, hip abductions, ankle plantar flexions, and ankle dorsiflexions. Thirdly, a set of balance exercises including knee bends, backwards walking, walking and turning around, sideways walking, tandem stance, tandem walk, one leg stand, heel walking, toe walking, toe to heel walking backwards, sit-to-stand, and stair walking.~Finally, participants are instructed to walk at their usual pace for at least 10 minutes.
Study: NCT03574935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: External Chinese medicine
Description: External Chinese medicine:~For patients in the treatment group, they will accept one of three specific External Chinese medicine according to their lesions and corresponding syndromes:~1. Chinese herb of Clear heat-Remove dampness-Detoxicate for patients belong to heat syndrome;~2. Chinese herb of Activating blood-Removing stasis for patients belong to stasis syndrome;~3. Chinese herb of Supplement deficiency-Generate muscles for patients belong to deficiency syndrome.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: External Chinese medicine
Description: External Chinese medicine:~For patients in the treatment group, they will accept one of three specific External Chinese medicine according to their lesions and corresponding syndromes:~1. Chinese herb of Clear heat-Remove dampness-Detoxicate for patients belong to heat syndrome;~2. Chinese herb of Activating blood-Removing stasis for patients belong to stasis syndrome;~3. Chinese herb of Supplement deficiency-Generate muscles for patients belong to deficiency syndrome.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: External Western medicine
Description: For patients in the control group, they will accept one of three specific external Western medicine according to their lesions:~1.Ethacridine Lactate Solution(lesions with much effusion)； 2.1% Sulfadiazine Silver Cream（lesions with infection）； 3.rb-bFGF(lesions with no slough and look clear).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: External Western medicine
Description: For patients in the control group, they will accept one of three specific external Western medicine according to their lesions:~1.Ethacridine Lactate Solution(lesions with much effusion)； 2.1% Sulfadiazine Silver Cream（lesions with infection）； 3.rb-bFGF(lesions with no slough and look clear).
Study: NCT01480141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992 (Afatinib)
Description: Patients will receive treatment with afatinib 40mg orally daily for a minimum of 2 weeks
Study: NCT03650023

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: White egg
Description: White egg capsule was consumed within 15 min, and then 2-h oral sucrose tolerance test was conducted.
Study: NCT00730327

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioEnterics® Intragastric Balloon
Description: Inflatable balloon inserted into the stomach.
Study: NCT04070352

Intervention type: DRUG
Intervention: Fidaxomicin
Description: patients who are receiving fidaxomicin are enrolled into the study, blood is obtained for analysis, EMR and outcome data collected regarding their CDI
Study: NCT02572258

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional cookie
Study: NCT00856479

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Infuse Bone Morphogenic Protein (BMP) 2
Description: Infuse is a synthetic bone morphogenic protein which means it has the ability to help your bone to form and heal if inserted in the fracture site. Infuse may be the first commercially available product approved by Health Canada to accelerate the healing of long bone non-unions requiring surgical intervention.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: iliac crest autograft
Description: A piece of the patients iliac crest bone is take and mixed with bone from a bone bank to supplement the bone loss in the fracture
Study: NCT01895816

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: coated tablet
Description: this supplement contains 700 mg of 8 natural herbals: Citrus \& ZINGIBER OFFICINALE \& Onion \& Ocimum basilicum \& Cinnamomum zelanicum \& Citrullus lanatus \& Citrullus vulgaris \& Daucus carota
Study: NCT04467177

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 30% glucose
Description: Male neonates will receive 2 ml of 30% glucose two minutes prior to circumcision

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Male neonates will receive 2 ml of sterile water two minutes prior to circumcision
Study: NCT03096223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK4083
Description: IV administration
Study: NCT00262080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ecallantide
Description: dose of 30 mg (10 mg/ml) given as 3 subcutaneous injections.
Study: NCT02833272

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMPOWER Educational Brochure
Description: The EMPOWER educational brochure explains the risk of benzodiazepine and non-benzodiazepine sedative use to patients with a current prescription. The brochure also provides a tapering schedule if the patient chooses to discontinue taking the drug.
Study: NCT01649180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: Axitinib 5 mg orally with food every 12 hours. One cycle=28 days.
Study: NCT00868569

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE + folfox 4
Description: tace: oxaliplatin 100mg + fudr 1g + mmc 10mg + iodine 2ml~folfox4

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAC + folfox4
Description: tac: oxaliplatin 100mg + fudr 1g + mmc 10mg~folfox4
Study: NCT01987154

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Marketed cow milk-based premature infant formula

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Marketed extensively hydrolyzed casein infant formula
Study: NCT04219137

Intervention type: GENETIC
Intervention: Molecular Profiling
Description: This is a correlative study collecting biosamples to evaluate genomic characteristics and treatment outcomes of gastroesophageal adenocarcinoma.

Intervention type: GENETIC
Intervention: Molecular Profiling
Description: This is a correlative study collecting biosamples to evaluate genomic characteristics and treatment outcomes of gastroesophageal adenocarcinoma.
Study: NCT03230396

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamingum Sport
Description: Vitamin -supplemented chewing gum

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamingum Immunity
Description: Vitamin -supplemented chewing gum
Study: NCT00262080

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Phosphate Buffer Saline (PBS),
Description: given as three 1mL subcutaneous injections.
Study: NCT04895163

Intervention type: PROCEDURE
Intervention: Laparoscopic appendectomy
Description: Laparoscopic appendectomy performed for acute appendicitis

Intervention type: PROCEDURE
Intervention: Laparoscopic appendectomy
Description: Laparoscopic appendectomy performed for acute appendicitis
Study: NCT03105596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide plus DICE Regimen
Description: Chidamide 20mg orally d1, 4, 8, 11, 15, 18; Dexamethasone 10mg，ivg, d1-4; ifosfamide 1g/m2, ivg, d1-4, given over 4 hours; Mesna 0.4g, 0,4,8,12 hours during Ifosfamide transfusion, ivg, d1-4; Cisplatin 25mg/m2, ivg, d1-4; Etoposide 60mg/m2, ivg. d1-4.
Study: NCT01319643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: The lowest inspiratory fraction of oxygen between 21 and 100% in as a short time as possible to maintain SpO2 between 94 and 98% or PaO2 between 70 and 100 mmHg.
Study: NCT00808249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7325
Description: 2 tablets taken twice a day for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7325
Description: 2 tablets taken twice a day for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7325
Description: 2 tablets taken twice a day for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 2 tablets taken twice a day for 28 days
Study: NCT02145923

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Peripheral blood stem cell mobilisation and collection

Intervention type: DRUG
Group type: OTHER
Intervention: High-dose chemotherapy
Description: High-dose chemotherapy will be performed according to protocols ICE and BEAM (standard scheme)

Intervention type: DRUG
Group type: OTHER
Intervention: Bone marrow derived allogeneic MMSCs infusion

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Autologous peripheral blood stem cells infusion
Study: NCT03009201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Given PO
Study: NCT04606654

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Handgrip strength training without Blood flow restriction
Description: Participants of this group will get exercise training through hand grip strengthener and DMOOSE fitness resistance bar. Participants will contract his/her forearm at a rate of 15 times/min (1 contraction every 4 sec). The subjects will train for 20 min, 3 days per week for 2 weeks (total 6 sessions), under the supervision of a principle investigator. Participants will be allowed to take 1 min rest periods, after the completion of 5 minutes of training.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Handgrip strength training with Blood flow restriction
Description: Participants of this group will get exercise training through hand grip strengthener and DMOOSE fitness resistance bar. Participants will contracts his/her forearm at a rate of 15 times/min (1 contraction every 4 sec). The subjects will train for 20 min, 3 days per week for 2 weeks (total 6 sessions), under the supervision of a principle investigator. Participants will be allowed to take 1 min rest periods, after the completion of 5 minutes of training. However, for one of the limbs the pneumatic blood pressure cuff will be placed on the upper arm, 4 cm proximal to the ante-cubital fossa. The decision which arm would receive the occlusion during training will be randomized to avoid a dominant or non-dominant hand bias. During experimental group training blood pressure cuff will be partially inflated (80 mmHg) to ensure venous occlusion. Participants will be allowed to take 1 min rest periods, after the completion of 5 minutes of training while the cuff remained inflated.
Study: NCT01021072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MABp1
Description: 0.25 mg/kg,0.75 mg/kg,1.25 mg/kg, 3.75 mg/kg IV (in the vein) on day 1 of each 21 day cycle until progression or unacceptable toxicity develops.
Study: NCT03230396

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control chewing gum. No vitamin content.
Study: NCT00389597

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cervical Artificial Disc
Description: Cervical artificial disc mechanical device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cervical Artificial Disc
Description: Cervical artificial disc mechanical device
Study: NCT03592654

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: infant telehelp
Description: Adapted from Early Start Denver Model (ESDM), a naturalistic developmental behavioral intervention
Study: NCT05182190

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: White bread
Description: Toasted white bread

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Black beans whole boiled
Description: Whole boiled black beans with spaghetti sauce

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Knife Mill pasta
Description: Black bean pasta (KM) with spaghetti sauce

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Combo Flour Pasta
Description: Black bean pasta (Combo) with spaghetti sauce (medium protein flour)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cyclone Flour Pasta
Description: Black bean pasta (Cyclone) with spaghetti sauce (low protein flour)
Study: NCT01206075

Intervention type: DRUG
Group type: OTHER
Intervention: Mozobil
Description: Previously mobilized splenectomized patients who failed to yield sufficient numbers of cells with Mozobil alone will receive low doses G-CSF subcutaneously (starting at 2.5µg/kg/day and adjusted to the degree of leukocytosis), and Mozobil at 240µg/kg starting on the 4th or 5th day of G-CSF, followed by one to three leukaphereses. Previously non-splenectomized patients who failed to yield sufficient numbers of cells with Mozobil alone will receive G-CSF at 10µg/kg/day subcutaneously for 4-7 days, and Mozobil at 240µg/kg starting on the 4th or 5th day of G-CSF, followed by one to three leukaphereses.

Intervention type: DRUG
Group type: OTHER
Intervention: Mozobil
Description: Previously mobilized splenectomized patients who failed to yield sufficient numbers of cells with G-CSF in the previous study will receive low doses G-CSF subcutaneously (starting at 2.5µg/kg/day and adjusted to the degree of leukocytosis), and Mozobil at 240µg/kg starting on the 4th or 5th day of G-CSF, followed by one to three leukaphereses. Previously non-splenectomized patients who failed to yield sufficient numbers of cells with G-CSF in the previous study will receive G-CSF at 10µg/kg/day subcutaneously for 4-7 days, and Mozobil at 240µg/kg starting on the 4th or 5th day of G-CSF, followed by one to three leukaphereses.

Intervention type: DRUG
Group type: OTHER
Intervention: Mozobil
Description: Up to sixteen patients (splenectomized and non-splenectomized) who were not previously mobilized will receive Mozobil at 240µg/kg for one to three days, followed by one to three leukaphereses.
Study: NCT00094575

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endovascular Repair
Description: Endovascular Repair

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Open Repair
Description: Standard Open Repair
Study: NCT02994017

Intervention type: OTHER
Group type: OTHER
Intervention: cardiopulmonary exercise testing
Description: The Cardiopulmonary exercise testing (CPET) was performed at the beginning of the study, the same at each center. Each patient underwent a symptom-limited incremental exercise test on an ergometric bicycle (Ergoline-Ergometrics 800®). The protocol included a warm-up period of 3 min at 20 W followed by a progressively increasing work rate (WR) in a ramp fashion and then 3 min recovery. The ramped WR increment was individualized (range,8-30 W/min). during exercise, heart rate (HR) was monitored continuously by 12-lead ECG, and arterial oxygen saturation (SpO2) was measured by pulse oximetry (Nellcor N-395). The expired gases were analyzed with an Ergocard®, focusing on oxygen consumption(VO2), carbon dioxide production (VCO2), minute ventilation (VE), and tidal volume (VT).
Study: NCT03072953

Intervention type: DRUG
Group type: OTHER
Intervention: APD334
Description: APD334 active treatment
Study: NCT03001154

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Face-to-face Virtual Reality Exposure Therapy
Description: In session, systematic, hierarchical exposure to feared stimuli with therapist.
Study: NCT03399968

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ESWT
Description: at low energy, shockwaves are applied non-invasively at the injury level and 5 segments up and down of the spinal cord paravertebrally left and right

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ESWT
Description: the ESWT therapy head is positioned at the level of injury and is moved up and down identically as described in the Verum intervention group (ESWT) but without application of shockwaves. The sound which is normally produced by shockwave generation is played by high quality sound recordings in the same amount as in the Verum group
Study: NCT05110534

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: additional oral hygiene appointments
Description: Two additional preventive sessions including oral hygiene instructions one week before the date of the general anaesthesia treatment and at the control visit about a week after the general anaesthesia.
Study: NCT03830736

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Oat Beverage 1
Description: Oat based beverage with added different concentration of extracted oat component.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Oat Beverage 2
Description: Oat based beverage with added different concentration of extracted oat component.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Oat Beverage 3
Description: Oat based beverage with added different concentration of extracted oat component.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Oat Beverage 4
Description: Oat based beverage with added different concentration of extracted oat component.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Control product
Description: Glucose based beverage without added test components is used as control product